Towa Pharmaceutical expanding Japan-made generics shipments to US market.
Context
What happened: Towa Pharmaceutical plans to begin exporting Japan-made generic injectable drugs to the U.S. as early as 2028, aiming to use its quality control capabilities to enter the American market.
Key numbers: Target start date is as early as 2028; U.S. sales network came from a 2020 acquisition of a Spanish drugmaker.
Why it matters: The company is shifting toward high-value-added injectable drugs, per CEO Yoshida, and will use its U.S. sales network to compete in the American generics market.
Why it matters
The company is shifting toward high-value-added injectable drugs, per CEO Yoshida, and will use its U.S. sales network to compete in the American generics market.